Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 29Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13Ipilimumab 12Capecitabine 12durvalumab 11Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Filgrastim × Clear all
NCT03907488 2026-05-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

NCT03036488 2025-10-29

MK-3475-522

Merck Sharp & Dohme LLC

Phase 3 Completed
1,174 enrolled 1 FDA
Breast

Triple Negative Breast Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
377 enrolled 17 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡